OncoCyte (NASDAQ:OCX) PT Raised to $4.25 at Needham & Company LLC

OncoCyte (NASDAQ:OCX) had its price target lifted by Needham & Company LLC from $3.60 to $4.25 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com assumed coverage on shares of OncoCyte in a report on Wednesday. They issued a sell rating on the stock. Stephens restated an equal weight rating and issued a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Finally, Benchmark restated a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte in a report on Monday, April 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Hold and an average price target of $4.06.

OncoCyte Trading Up 1.6 %

Shares of NASDAQ OCX opened at $2.48 on Wednesday. OncoCyte has a 1 year low of $2.08 and a 1 year high of $6.20. The company’s 50-day moving average is $2.90 and its 200 day moving average is $3.03.

Insider Activity

In other news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the acquisition, the insider now directly owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Andrew Arno purchased 33,898 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the acquisition, the director now directly owns 69,054 shares in the company, valued at approximately $203,709.30. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the transaction, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The disclosure for this purchase can be found here. Insiders have bought a total of 2,457,288 shares of company stock worth $7,176,400 over the last 90 days. 1.94% of the stock is currently owned by insiders.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.